Free Trial

Envista (NVST) Competitors

Envista logo
$17.78 +0.08 (+0.45%)
As of 05/20/2025 03:58 PM Eastern

NVST vs. SNN, PEN, STVN, GKOS, NARI, INSP, IRTC, BLCO, TMDX, and SLNO

Should you be buying Envista stock or one of its competitors? The main competitors of Envista include Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.

Envista vs.

Smith & Nephew (NYSE:SNN) and Envista (NYSE:NVST) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Smith & Nephew received 414 more outperform votes than Envista when rated by MarketBeat users. Likewise, 54.10% of users gave Smith & Nephew an outperform vote while only 32.71% of users gave Envista an outperform vote.

CompanyUnderperformOutperform
Smith & NephewOutperform Votes
449
54.10%
Underperform Votes
381
45.90%
EnvistaOutperform Votes
35
32.71%
Underperform Votes
72
67.29%

Smith & Nephew has a net margin of 0.00% compared to Envista's net margin of -44.56%. Envista's return on equity of 3.86% beat Smith & Nephew's return on equity.

Company Net Margins Return on Equity Return on Assets
Smith & NephewN/A N/A N/A
Envista -44.56%3.86%2.21%

Smith & Nephew currently has a consensus price target of $28.00, suggesting a potential downside of 4.70%. Envista has a consensus price target of $20.08, suggesting a potential upside of 12.92%. Given Envista's stronger consensus rating and higher possible upside, analysts clearly believe Envista is more favorable than Smith & Nephew.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Envista
1 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.14

In the previous week, Envista had 2 more articles in the media than Smith & Nephew. MarketBeat recorded 8 mentions for Envista and 6 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 1.71 beat Envista's score of 1.13 indicating that Smith & Nephew is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Envista
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

25.6% of Smith & Nephew shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by insiders. Comparatively, 1.3% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Smith & Nephew has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Envista has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Smith & Nephew has higher revenue and earnings than Envista. Envista is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew$5.81B2.21$263M$2.1613.60
Envista$2.50B1.20-$1.12B-$6.53-2.72

Summary

Smith & Nephew beats Envista on 10 of the 18 factors compared between the two stocks.

Get Envista News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVST and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVST vs. The Competition

MetricEnvistaDental equipment & supplies IndustryMedical SectorNYSE Exchange
Market Cap$3.01B$3.87B$5.42B$19.70B
Dividend YieldN/A2.06%5.22%3.84%
P/E Ratio-2.7439.4326.8335.12
Price / Sales1.201.39393.8634.12
Price / Cash12.916.5738.2517.51
Price / Book1.040.686.874.78
Net Income-$1.12B-$146.24M$3.22B$1.02B
7 Day Performance-4.92%3.10%5.65%0.90%
1 Month Performance17.07%17.22%13.54%11.10%
1 Year Performance-2.68%-20.48%18.16%5.28%

Envista Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVST
Envista
4.0514 of 5 stars
$17.78
+0.5%
$20.08
+12.9%
-2.7%$3.01B$2.50B-2.7412,700Positive News
Gap Up
SNN
Smith & Nephew
2.266 of 5 stars
$28.43
+0.3%
$28.00
-1.5%
+12.9%$12.45B$5.81B13.1620,100News Coverage
PEN
Penumbra
4.4338 of 5 stars
$296.98
-0.1%
$302.40
+1.8%
+39.5%$11.50B$1.24B873.473,900Positive News
STVN
Stevanato Group
1.2604 of 5 stars
€23.64
-1.5%
N/A+21.2%$7.16B$1.10B50.304,650Positive News
GKOS
Glaukos
4.6725 of 5 stars
$94.57
+5.1%
$134.67
+42.4%
-10.7%$5.40B$404.52M-32.95780News Coverage
Positive News
NARI
Inari Medical
0.472 of 5 stars
$79.97
flat
$69.22
-13.4%
N/A$4.68B$493.63M-59.24800News Coverage
INSP
Inspire Medical Systems
4.7118 of 5 stars
$156.54
+3.5%
$211.91
+35.4%
-3.4%$4.62B$840.11M90.49760Positive News
Gap Up
IRTC
iRhythm Technologies
1.3027 of 5 stars
$137.80
+0.1%
$128.55
-6.7%
+52.5%$4.40B$618.59M-37.861,790Positive News
BLCO
Bausch + Lomb
4.3015 of 5 stars
$11.91
+5.6%
$15.50
+30.2%
-19.2%$4.21B$4.83B-13.0812,500Gap Up
TMDX
TransMedics Group
1.4365 of 5 stars
$118.73
+6.5%
$126.70
+6.7%
-10.0%$4.02B$488.23M126.31210Positive News
SLNO
Soleno Therapeutics
4.8661 of 5 stars
$76.70
-0.1%
$106.78
+39.2%
+59.6%$3.87BN/A-23.1030News Coverage
Positive News

Related Companies and Tools


This page (NYSE:NVST) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners